NCT02794428View on ClinicalTrials.gov

Chemoprevention of Gastric Carcinogenesis

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

September 19, 2016

Primary Completion Date

December 20, 2022

Study Completion Date

July 1, 2024

Conditions
Gastric CancerGastric Intestinal Metaplasia
Interventions
DRUG

Eflornithine

Eflornithine\*, 2 tablets, Oral, Daily for 18 months

OTHER

Eflornithine placebo

Eflornithine placebo, 2 tablets, Oral, Daily for 18 months

Trial Locations (2)

Unknown

Ministry of Health, Hospital de Occidente, Copán

University of Puerto Rico, Comprehensive Cancer Center, San Juan

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Cancer Prevention Pharmaceuticals, Inc.

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER